Vitamin D and L-cysteine Levels Correlate Positively with GSH and Negatively with Insulin Resistance Levels in the Blood of Type 2 Diabetic Patients
Overview
Authors
Affiliations
Background/objectives: Vitamin D, L-cysteine (LC) and glutathione (GSH) levels are lower in the blood of diabetic patients. This study examined the hypothesis that the levels of vitamin D and LC correlate with those of GSH in the blood of type 2 diabetic patients (T2D), and that vitamin D and LC upregulate glutamate-cysteine ligase (GCLC), which catalyzes GSH biosynthesis, in cultured monocytes.
Subjects/methods: Fasting blood was obtained after written informed consent from T2D (n=79) and healthy controls (n=22). U937 monocytes were pretreated with 1,25 (OH)2 vitamin D (0-25 nM) or LC (0-500 μM) for 24 h and then exposed to control or high glucose (25 mM) for 4 h.
Results: Plasma levels of vitamin D, LC, GSH and GCLC protein were significantly lower in T2D versus those in age-matched healthy controls. Multiple linear regression analyses and adjustment for body weight showed a significant positive correlation between plasma levels of vitamin D (r=0.26, P=0.05) and LC (r=0.81, P=0.001) and that of GSH, and between LC and vitamin D (r=0.27, P=0.045) levels. Plasma levels of GSH (r=-0.34, P=0.01) and LC (r=-0.33, r=0.01) showed a negative correlation with triglyceride levels. Vitamin D correlated inversely with HbA1C (-0.30, P=0.01) and homeostatic model assessment insulin resistance (r=-0.31, P=0.03), which showed a significant positive correlation with triglycerides (r=0.44, P=0.001) in T2D. Cell culture studies demonstrate that supplementation with vitamin D and LC significantly increased GCLC expression and GSH formation in control and high-glucose-treated monocytes.
Conclusions: This study suggests a positive relationship between the concentrations of the micronutrients vitamin D and LC and that of GSH. Some of the beneficial effects of vitamin D and LC supplementation may be mediated by an increase in the levels of GSH and a decrease in triglyceride levels in T2D patients.
Ng H, Zhang L, Tan J, Hui R, Yuen M, Seto W Liver Int. 2025; 45(3):e70023.
PMID: 39950834 PMC: 11827547. DOI: 10.1111/liv.70023.
Jain S, Margret J, Abrams S, Levine S, Bhusal K Nutrients. 2024; 16(13).
PMID: 38999752 PMC: 11243476. DOI: 10.3390/nu16132004.
Kurdi C, Lelovics V, Hesszenberger D, Lajtai A, Lakatos A, Herczeg R Int J Mol Sci. 2023; 24(15).
PMID: 37569834 PMC: 10419978. DOI: 10.3390/ijms241512458.
Lei X, Zhou Q, Wang Y, Fu S, Li Z, Chen Q Sci Rep. 2023; 13(1):12343.
PMID: 37524765 PMC: 10390579. DOI: 10.1038/s41598-023-39469-9.
Increased glucose availability sensitizes pancreatic cancer to chemotherapy.
Vaziri-Gohar A, Hue J, Abbas A, Graor H, Hajihassani O, Zarei M Nat Commun. 2023; 14(1):3823.
PMID: 37380658 PMC: 10307839. DOI: 10.1038/s41467-023-38921-8.